Table 1.
Unified response rates of advanced thymoma patients treated with anthracycline-based or non-anthracycline-based chemotherapy regimens
| Regimen | Author, year | Study design | Stage | No. of patients | Responders | RR | PFS | OS |
|---|---|---|---|---|---|---|---|---|
| Anthracycline-containing regimens | ||||||||
| ADOC | Fornasiero et al. (1991) | S | III/IVa/IVb | 37 | 34 | 91.8 % | 12 mos | 15 mos |
| PAC | Loehrer et al. (1994) | G | IV | 29 | 15 | 51.7 % | 11.8 mos | 37.7 mos |
| PAC (+XRT) | Loehrer et al. (1997) | G | III | 23 | 16 | 69.6 % | – | 93 mos |
| ADOC | Rea et al. (1993) | S | III/IVa | 16 | 12 | 75.0 % | – | 66 mos |
| ADOC | Berruti et al. (1999) | S | III/IVa | 16 | 13 | 81.3 % | 33.2 mos | 47.5 mos |
| PAC | Kim et al. (2004) | G | III/IVa/IVb | 22 | 17 | 77.3 % | – | – |
| PAE (+XRT) | Lucchi et al. (2006) | S | III/IVA | 30 | 22 | 73.3 % | – | – |
| CAMP | Yokoi et al. (2007) | S | IVa/IVb | 14 | 13 | 92.9 % | – | – |
| Dose-dense CODE | Kunitoh et al. (2009) | G | IVa/IVb | 27 | 16 | 59.3 % | 0.79 year | 6.1 year |
| CarboAMR | Kawashima et al. (2013) | G | Invasive | 18 | 3 | 16.7 % | 7.6 mos | Not reached |
| Total | 232 | 161 | 69.4 % | |||||
| Non-anthracycline-containing regimens | ||||||||
| PE | Giaccone et al. (1996) | G | III/IV/rec | 16 | 9 | 56 % | 2.2 year | 4.3 year |
| VIP | Loehrer et al. (2001) | G | III/IVa/IVb | 20 | 7 | 35 % | 11.9 mos | 31.6 mos |
| VIP | Grassin et al. (2011) | G | IIIB/IVA/IVB | 16a | 4a | 25 %a | 13.1 mos | Not reached |
| CarboPTX | Takeda et al. (2013) | G | III/IVa/IVb | 21 | 6 | 42.9 % | 16.7 mos | Not reached |
| CDDP/DTX | Park et al. (2013) | G | III/IVa/IVb | 9 | 5 | 55.6 % | – | – |
| Total | 82 | 31 | 37.8 % | |||||
G prospective multicenter group phase II trial, S single-center experience, mos months, RR objective response rate, ADOC adriamycin, cisplatin, vincristine and cyclophosphamide, PAC cisplatin, adriamycin and cyclophosphamide, PAE cisplatin, adriamycin and etoposide, CAMP PAC = cisplatin, adriamycin, methylprednisolone and cyclophosphamide, CODE adriamycin, cisplatin, vincristine and etoposide, PE cisplatin and etoposide, VIP vincristine, ifosfamide and cisplatin, CarboPTX carboplatin and paclitaxel
aIncluding four patients with thymic carcinoma in the VIP trial